Mala K. Maini
Gower Street
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications
Preserved CD4 + T cell helper function and coordinated antiviral immunity in people with HBV/HIV co-infection on long-term therapy.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026
Abortive infection: T cells as early, antibody-independent defenders.
Journal: Nature reviews. Immunology
Published: April 02, 2026
Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells.
Journal: Journal for immunotherapy of cancer
Published: January 19, 2026
Corrigendum to "Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response" [J Hepatol (2025) 101382].
Journal: JHEP reports : innovation in hepatology
Published: October 24, 2025
Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).
Journal: Hepatology (Baltimore, Md.)
Published: September 19, 2025
Black Hole Spectroscopy and Tests of General Relativity with GW250114.
Journal: Physical review letters
Published: September 12, 2025
GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.
Journal: Physical review letters
Published: August 13, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection.
Journal: medRxiv : the preprint server for health sciences
Published: April 16, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection.
Journal: Gut
Published: April 01, 2025
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection.
Journal: Nature communications
Published: March 24, 2025
Last Updated: 09/26/2026